CliffBio
small molecule

UCERIS

BUDESONIDE

Loss of exclusivity—loss of exclusivity
CompanySalix Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameUCERIS
Active ingredientBUDESONIDE
Strength2MG/ACTUATION
Dosage formAEROSOL, FOAM
RouteRECTAL
ModalitySmall molecule
FDA approvalOctober 2014
Marketing statusRX

More from Salix Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.